B2M and renal cell carcinoma: In much the same way, it has been reported that CTX-130, which is a modified anti-CD70 allo -CAR-T used for the disruption of the CD70 and β2M genes so as to decrease the fratricide and allorejection, elicits a durable complete response in an individual suffering from Renal Cell Carcinoma (RCC) (110), This may indicate that, even in solid tumors, the technique is actually enhancing the allogeneic CAR-Ts’ activity.